Pharma Funds Performance

Pharma and health care funds: Defensive bets amid growing volatility

Altogether, 26 funds focused on pharma and healthcare collectively manage Rs 30,306 crore. Some of them offer exposure to global pharma stocks

Limit exposure to pharma and healthcare funds to 5% of equity portfolio

Improving US generic market outlook is driving the current rebound, but brace for periodic drawdowns

Pharma funds lag sectoral peers despite Covid tailwind as US market weighs

In the year to date, the Nifty pharma index has returned 8.8 per cent, with 10 of its constituents giving negative returns

China's recovery from coronavirus outbreak, drug demand lift pharma funds

Easing of supply chain issues, hydroxychloroquine opportunity boost sentiments

Coronavirus-induced lockdown in China can put the brakes on pharma funds

Money managers say domestic API manufacturers can stall impact from Chinese lockdown

Why IT, pharma funds can be safe bets for investors in a bad market

Investors, however, need to understand their prospects before deciding to raise their exposure to these export-oriented sectors

Rupee fall gives leg up to IT, pharma funds, may help ease margin pressure

IT and pharma funds have returned 4.4% and 1.77% in the past month, respectively

Pharma funds make a comeback; now rises 17.3% for a one-year period

Attractive valuations have spurred fund houses to launch new funds in this category as well

Pharma funds worst sectoral performers in a year

The funds have shed 8.5%, even as Sensex has returned 16%; effectively that's a 25% underperformance